Merck & Co., Inc. (NYSE:MRK) Shares Sold by Buckley Wealth Management LLC

Buckley Wealth Management LLC lowered its holdings in Merck & Co., Inc. (NYSE:MRK) by 3.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 76,927 shares of the company’s stock after selling 2,430 shares during the quarter. Merck & Co., Inc. accounts for about 3.2% of Buckley Wealth Management LLC’s holdings, making the stock its 9th biggest position. Buckley Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $6,476,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Nuveen Asset Management LLC raised its stake in shares of Merck & Co., Inc. by 6,517.4% during the 2nd quarter. Nuveen Asset Management LLC now owns 24,307,332 shares of the company’s stock worth $2,038,169,000 after buying an additional 23,940,007 shares during the last quarter. BlackRock Inc. raised its stake in shares of Merck & Co., Inc. by 2.3% during the 2nd quarter. BlackRock Inc. now owns 191,863,408 shares of the company’s stock worth $16,087,745,000 after buying an additional 4,397,580 shares during the last quarter. FMR LLC raised its stake in shares of Merck & Co., Inc. by 41.2% during the 1st quarter. FMR LLC now owns 11,111,444 shares of the company’s stock worth $924,139,000 after buying an additional 3,244,078 shares during the last quarter. Invesco Ltd. raised its stake in shares of Merck & Co., Inc. by 18.4% during the 2nd quarter. Invesco Ltd. now owns 18,309,138 shares of the company’s stock worth $1,535,222,000 after buying an additional 2,843,458 shares during the last quarter. Finally, Schroder Investment Management Group raised its stake in shares of Merck & Co., Inc. by 67.7% during the 2nd quarter. Schroder Investment Management Group now owns 6,381,329 shares of the company’s stock worth $535,075,000 after buying an additional 2,576,060 shares during the last quarter. 74.97% of the stock is owned by institutional investors.

Merck & Co., Inc. stock traded up $0.58 during midday trading on Friday, reaching $84.34. 5,944,307 shares of the company were exchanged, compared to its average volume of 8,180,964. The company has a market capitalization of $213.25 billion, a price-to-earnings ratio of 19.43, a P/E/G ratio of 1.69 and a beta of 0.53. The firm’s 50-day simple moving average is $84.58 and its 200-day simple moving average is $82.23. Merck & Co., Inc. has a 1 year low of $66.10 and a 1 year high of $87.35. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.14. The firm had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $10.94 billion. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.06 EPS. On average, analysts forecast that Merck & Co., Inc. will post 4.92 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, October 7th. Investors of record on Monday, September 16th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.61%. The ex-dividend date was Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio is presently 50.69%.

Several research analysts have recently issued reports on MRK shares. Societe Generale set a $105.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Credit Suisse Group reaffirmed a “buy” rating and set a $95.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, August 7th. ValuEngine downgraded Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Bank of America set a $97.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Thursday, July 11th. Finally, Morgan Stanley lifted their price objective on Merck & Co., Inc. from $84.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, June 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have issued a buy rating to the company. Merck & Co., Inc. has a consensus rating of “Buy” and an average price target of $93.29.

In related news, EVP Richard R. Deluca sold 6,427 shares of Merck & Co., Inc. stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the sale, the executive vice president now owns 103,223 shares in the company, valued at approximately $8,783,245.07. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.27% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: Marijuana Stocks

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply